CCH

Endo Presents New Data at the American Podiatric Medical Association Annual Meeting

Retrieved on: 
Thursday, July 13, 2023

DUBLIN, July 13, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that new data from a Phase 1 study of collagenase clostridium histolyticum (CCH) in patients with plantar fibromatosis will be presented during the American Podiatric Medical Association's (APMA) annual scientific meeting.

Key Points: 
  • DUBLIN, July 13, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that new data from a Phase 1 study of collagenase clostridium histolyticum (CCH) in patients with plantar fibromatosis will be presented during the American Podiatric Medical Association's (APMA) annual scientific meeting.
  • The meeting is taking place now through July 16 in Nashville, Tenn.
  • Results from the Phase 1 clinical study showed improvement in nodule hardness and in patient and physician satisfaction scores.
  • Endo has completed Phase 2 and anticipates that the pivotal Phase 3 program will begin later this year.

Wolters Kluwer launches new solution to empower multinational enterprises to meet their OECD Pillar Two reporting requirements

Retrieved on: 
Sunday, July 9, 2023

Country by Country Reporting (CbCR): The platform’s CbCR and global tax provision modules can provide end-to-end management of Pillar Two, interconnecting key tax processes with the data and reporting needs of Pillar Two.

Key Points: 
  • Country by Country Reporting (CbCR): The platform’s CbCR and global tax provision modules can provide end-to-end management of Pillar Two, interconnecting key tax processes with the data and reporting needs of Pillar Two.
  • Templated Pillar Two Calculation and Schedules: Helps provide precise Pillar Two reporting in an efficient manner, eliminating data integrity challenges and manual management of the Pillar Two calculations.
  • With multinational enterprises facing increasingly complex reporting obligations, Wolters Kluwer recognises the need for an innovative tool that allows for timely adaptation, simplifies processes, increases the efficiency of multinational tax teams, and unleashes greater potential for growth.
  • What we have today is just the beginning with more on our Pillar Two roadmap to come.”

Lobe Sciences Initiates Phase 1 Clinical Trial of L-130

Retrieved on: 
Tuesday, June 27, 2023

Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to treat rare diseases today announced the initiation of a Phase 1, pharmacokinetic clinical study of L-130, a proprietary stabilized psilocin analogue drug candidate in healthy volunteers.

Key Points: 
  • Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to treat rare diseases today announced the initiation of a Phase 1, pharmacokinetic clinical study of L-130, a proprietary stabilized psilocin analogue drug candidate in healthy volunteers.
  • We believe L-130, with its potent activity on the serotonin receptor may offer a unique solution to CCH patients” added Mr. Young.
  • All subjects will be evaluated for impacts on cognition and anxiolytic effects on day 1, 7 and 28.
  • Full completion of the study is expected in Q3 2023 and results will be used to determine L-130 dose levels for a planned Phase 2a study in chronic cluster headaches.

Coca-Cola HBC and Genpact Partner to Transform Operations and Drive Future Growth

Retrieved on: 
Monday, June 26, 2023

SOFIA, Bulgaria, June 26, 2023 /PRNewswire/ -- Coca-Cola HBC (CCH), one of the largest Coca-Cola strategic bottlers, and Genpact (NYSE: G), a global professional services firm focused on delivering outcomes that transform businesses, today announced a partnership to accelerate digital transformation for CCH's finance operations.

Key Points: 
  • "We are constantly focused on improving customer service and operational competitiveness across our markets," said Spyros Mello, Strategy and Transformation Director, CCH.
  • The multi-year engagement is set to drive future growth and competitive advantage for CCH.
  • "Most companies today are looking at ways to leverage artificial intelligence to build agile operations and drive efficiencies.
  • Genpact's delivery center in Sofia, Bulgaria, will serve as a hub to deliver its Data-Tech-AI and Digital Operations services.

Coca-Cola HBC and Genpact Partner to Transform Operations and Drive Future Growth

Retrieved on: 
Thursday, June 22, 2023

SOFIA, Bulgaria and NEW YORK, June 22, 2023 /PRNewswire/ -- Coca-Cola HBC (CCH), one of the largest Coca-Cola strategic bottlers, and Genpact (NYSE: G), a global professional services firm focused on delivering outcomes that transform businesses, today announced a partnership to accelerate digital transformation for CCH's finance operations.

Key Points: 
  • "We are constantly focused on improving customer service and operational competitiveness across our markets," said Spyros Mello, Strategy and Transformation Director, CCH.
  • The multi-year engagement is set to drive future growth and competitive advantage for CCH.
  • "Most companies today are looking at ways to leverage artificial intelligence to build agile operations and drive efficiencies.
  • Genpact's delivery center in Sofia, Bulgaria, will serve as a hub to deliver its Data-Tech-AI and Digital Operations services.

Empowering Blockchain Advancement in Germany: CoinEx Sponsors BlockChance 23

Retrieved on: 
Wednesday, June 21, 2023

CoinEx , a global crypto exchange, recently announced its sponsorship of BlockChance 23, the fourth BlockChance conference so far, which will be held at Congress Center Hamburg (CCH) in Germany.

Key Points: 
  • CoinEx , a global crypto exchange, recently announced its sponsorship of BlockChance 23, the fourth BlockChance conference so far, which will be held at Congress Center Hamburg (CCH) in Germany.
  • This marks CoinEx’s first sponsorship of a blockchain exhibition in Germany, which showcases its commitment to the German market and its confidence in the future of crypto.
  • As one of Europe’s top blockchain conferences, BlockChance 23 will take place in the Free and Hanseatic City of Hamburg from June 28 to June 30.
  • As the conference approaches, we look forward to CoinEx’s debut at BlockChance 23 and wish the event a resounding success.

Wolters Kluwer named ‘Premier Leader’ in BPM Partners’ Vendor Landscape Matrix

Retrieved on: 
Tuesday, June 20, 2023

Wolters Kluwer CCH® Tagetik has followed up its success in last year’s BPM Partners Vendor Landscape Matrix by securing the top ranking of “Premier Leader” in the 2023-2024 edition.

Key Points: 
  • Wolters Kluwer CCH® Tagetik has followed up its success in last year’s BPM Partners Vendor Landscape Matrix by securing the top ranking of “Premier Leader” in the 2023-2024 edition.
  • BPM Partners, the leading authority on business performance management, recognized Wolters Kluwer CCH Tagetik for the fourth year in a row as a ‘Dominant’ vendor and for the second year in a row in the highest customer satisfaction level of ‘Outstanding’.
  • The widely respected Vendor Landscape Matrix analyzes empirical data to rank vendors in the space according to their relative market status and the customer satisfaction levels which they achieve.
  • “This top position of Premier Leader would indicate that Wolters Kluwer is consistently meeting or exceeding the requirements of their customers and the market at large,” said Craig Schiff President & CEO at BPM Partners.

Altera Digital Health and Columbus Community Hospital Extend Partnership by Seven Years

Retrieved on: 
Thursday, June 8, 2023

Altera Digital Health , a global health IT innovator, and Columbus Community Hospital (CCH), a community-owned, not-for-profit hospital in Columbus, Nebraska, today announced the hospital is extending its use of the Paragon® electronic health record (EHR) by seven years.

Key Points: 
  • Altera Digital Health , a global health IT innovator, and Columbus Community Hospital (CCH), a community-owned, not-for-profit hospital in Columbus, Nebraska, today announced the hospital is extending its use of the Paragon® electronic health record (EHR) by seven years.
  • Its usage of Paragon and partnership with Altera have given it the digital tools and support needed to continue elevating healthcare experiences for its patients, providers and other staff members.
  • “Columbus Community Hospital is dedicated to delivering compassionate, personalized care to every patient we serve, and having the right technology partner is essential to that commitment,” said Michael Hansen, President and CEO, Columbus Community Hospital.
  • “Our Paragon team has achieved significant momentum, and I’m excited to see what we can accomplish with Columbus Community Care as we move forward together.”

Endo Announces Publication of XIAFLEX® (collagenase clostridium histolyticum) Data Analysis in Peer-Reviewed Urology®

Retrieved on: 
Monday, June 5, 2023

Read the article here .

Key Points: 
  • Read the article here .
  • "The data analysis points to the importance of patient adherence to treatment protocol for efficacy and positive therapeutic outcomes when treating PD with XIAFLEX®," said Dr. Matthew J. Ziegelmann, urologist and lead author.
  • "Incremental Treatment Response by Cycle With Collagenase Clostridium Histolyticum for Peyronie's Disease: A Pooled Analysis of Two Phase 3 Trials" was submitted by authors Matthew Ziegelmann, M.D.
  • ; Yiqun Hu, M.D., Ph.D.; Qinfang Xiang, Ph.D.; Genzhou Liu, Ph.D.; Michael P. McLane, Ph.D.; and Landon Trost, M.D.

Endo Announces Publication of XIAFLEX® (collagenase clostridium histolyticum) Data Analysis in Peer-Reviewed Urology®

Retrieved on: 
Monday, June 5, 2023

Read the article here .

Key Points: 
  • Read the article here .
  • "The data analysis points to the importance of patient adherence to treatment protocol for efficacy and positive therapeutic outcomes when treating PD with XIAFLEX®," said Dr. Matthew J. Ziegelmann, urologist and lead author.
  • "Incremental Treatment Response by Cycle With Collagenase Clostridium Histolyticum for Peyronie's Disease: A Pooled Analysis of Two Phase 3 Trials" was submitted by authors Matthew Ziegelmann, M.D.
  • ; Yiqun Hu, M.D., Ph.D.; Qinfang Xiang, Ph.D.; Genzhou Liu, Ph.D.; Michael P. McLane, Ph.D.; and Landon Trost, M.D.